THE DARK INTELLIGENCE GROUP
21806 Briarcliff Dr.
Spicewood, TX 78669
512-264-7103 o
512-264-0969 f

Media Contact: Alan Ramsdell
info@darkreport.com

New Dark Daily White Paper Addresses Drug Resistance Testing

AUSTIN, TEXAS (March 27, 2023) — DarkDaily today announced the publication of “Virus Surveillance: Empowering Communities Through Early Genotypic Testing for HIV Drug Resistance,” a new white paper for the health laboratory community, produced in partnership with Thermo Fisher Scientific. This free white paper addresses several facets of HIV surveillance, including genotypic testing for drug-resistant mutations, virus cluster detection and response, and programs in action.

Health laboratories have an opportunity to position themselves at the forefront of reducing the harm of drug resistance and infectious disease. Exploring new options in viral genotyping HIV may be a promising path.

“Virus Surveillance: Empowering Communities Through Early Genotypic Testing for HIV Drug Resistance” is timely because experts say that HIV epidemiology data and care gaps driven by the impact of the COVID-19 pandemic warrant increased vigilance to identify HIV drug resistance (Section 1).

As antiretroviral drugs are a primary HIV therapy, the World Health Organization (WHO) warns that all antiretrovirals, including those from newer drug classes, are at risk of becoming partially or fully inactive due to the emergence of drug-resistant virus—it’s just a matter of time. This is an important point because if not prevented, HIV drug resistance can jeopardize the efficacy of medicines used to treat HIV, resulting in increased numbers of HIV infections, HIV-associated morbidity and mortality, and the need to develop new antiretrovirals.

Health laboratory directors interested in reducing the impact of emerging and harmful HIV drug-resistant mutations can use this white paper educational supplement for a new look at:

• Care gaps in viral load monitoring and drug resistance testing;
• Recent developments signaling new paths forward with HIV-1 testing; and
• Programs that monitor genetic evolution of drug-resistant mutations for people living with HIV.

This report specifically addresses drug-resistance testing needs, policy decisions influencing HIV testing, and insights from virus surveillance, cluster detection and response efforts. The white paper also includes a reference resource list.

Click here to download the free white paper. For additional information inquire at info@darkreport.com, or call Amanda Curtis at 512-264-7103.

About The Dark Intelligence Group

Since 1995, The Dark Intelligence Group has been the leading source of exclusive and reliable business intelligence about clinical laboratories, pathology groups, and laboratory diagnostics. The Dark Intelligence Group is the publisher of Dark Daily and The Dark Report, and each spring The Dark Intelligence Group hosts the renowned Executive War College on Diagnostics, Clinical Laboratory and Pathology Management.